|
1
|
Zhu AX, Hong TS, Hezel AF and Kooby DA:
Current management of gallbladder carcinoma. Oncologist.
15:168–181. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Wistuba II and Gazdar AF: Gallbladder
cancer: Lessons from a rare tumour. Nat Rev Cancer. 4:695–706.
2004. View
Article : Google Scholar : PubMed/NCBI
|
|
3
|
Lazcano-Ponce EC, Miquel JF, Muñoz N,
Herrero R, Ferrecio C, Wistuba II, Alonso de Ruiz P, Aristi Urista
G and Nervi F: Epidemiology and molecular pathology of gallbladder
cancer. CA Cancer J Clin. 51:349–364. 2001. View Article : Google Scholar
|
|
4
|
Batra Y, Pal S, Dutta U, Desai P, Garg PK,
Makharia G, Ahuja V, Pande GK, Sahni P, Chattopadhyay TK, et al:
Gallbladder cancer in India: A dismal picture. J Gastroenterol
Hepatol. 20:309–314. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Wu XS, Shi LB, Li ML, Ding Q, Weng H, Wu
WG, Cao Y, Bao RF, Shu YJ, Ding QC, et al: Evaluation of two
inflammation-based prognostic scores in patients with resectable
gallbladder carcinoma. Ann Surg Oncol. 21:449–457. 2014. View Article : Google Scholar
|
|
6
|
Butte JM, Matsuo K, Gönen M, D'Angelica
MI, Waugh E, Allen PJ, Fong Y, DeMatteo RP, Blumgart L, Endo I, et
al: Gallbladder cancer: Differences in presentation, surgical
treatment, and survival in patients treated at centers in three
countries. J Am Coll Surg. 212:50–61. 2011. View Article : Google Scholar
|
|
7
|
Li M, Zhang Z, Li X, Ye J, Wu X, Tan Z,
Liu C, Shen B, Wang XA, Wu W, et al: Whole-exome and targeted gene
sequencing of gallbladder carcinoma identifies recurrent mutations
in the ErbB pathway. Nat Genet. 46:872–876. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
McInnes KJ, Brown KA, Hunger NI and
Simpson ER: Regulation of LKB1 expression by sex hormones in
adipocytes. Int J Obes. 36:982–985. 2012. View Article : Google Scholar
|
|
9
|
Mans LA, Querol Cano L, van Pelt J,
Giardoglou P, Keune WJ and Haramis AG: The tumor suppressor LKB1
regulates starvation-induced autophagy under systemic metabolic
stress. Sci Rep. 7:73272017. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Yamada E and Bastie CC: Disruption of Fyn
SH3 domain interaction with a proline-rich motif in liver kinase B1
results in activation of AMP-activated protein kinase. PLoS One.
9:e896042014. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Zheng X, Chi J, Zhi J, Zhang H, Yue D,
Zhao J, Li D, Li Y, Gao M and Guo J: Aurora-A-mediated
phosphorylation of LKB1 compromises LKB1/AMPK signaling axis to
facilitate NSCLC growth and migration. Oncogene. 37:502–511. 2018.
View Article : Google Scholar
|
|
12
|
Jenne DE, Reimann H, Nezu J, Friedel W,
Loff S, Jeschke R, Müller O, Back W and Zimmer M: Peutz-Jeghers
syndrome is caused by mutations in a novel serine threonine kinase.
Nat Genet. 18:38–43. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Zhang H, Fillmore Brainson C, Koyama S,
Redig AJ, Chen T, Li S, Gupta M, Garcia-de-Alba C, Paschini M,
Herter-Sprie GS, et al: Lkb1 inactivation drives lung cancer
lineage switching governed by Polycomb Repressive Complex 2. Nat
Commun. 8:149222017. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Singh AK, Arya RK, Maheshwari S, Singh A,
Meena S, Pandey P, Dormond O and Datta D: Tumor heterogeneity and
cancer stem cell paradigm: Updates in concept, controversies and
clinical relevance. Int J Cancer. 136:1991–2000. 2015. View Article : Google Scholar
|
|
15
|
Kreso A and Dick JE: Evolution of the
cancer stem cell model. Cell Stem Cell. 14:275–291. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Sharma KL, Yadav A, Gupta A, Tulsayan S,
Kumar V, Misra S, Kumar A and Mittal B: Association of genetic
variants of cancer stem cell gene CD44 haplotypes with gallbladder
cancer susceptibility in North Indian population. Tumour Biol.
35:2583–2589. 2014. View Article : Google Scholar
|
|
17
|
Yin S, Li J, Hu C, Chen X, Yao M, Yan M,
Jiang G, Ge C, Xie H, Wan D, et al: CD133 positive hepatocellular
carcinoma cells possess high capacity for tumorigenicity. Int J
Cancer. 120:144–450. 2007. View Article : Google Scholar
|
|
18
|
Yamashita T, Ji J, Budhu A, Forgues M,
Yang W, Wang HY, Jia H, Ye Q, Qin LX, Wauthier E, et al:
EpCAM-positive hepatocellular carcinoma cells are tumor-initiating
cells with stem/progenitor cell features. Gastroenterology.
136:101–024. 2009. View Article : Google Scholar
|
|
19
|
Jin K, Xiang Y, Tang J, Wu G, Li J, Xiao
H, Li C, Chen Y and Zhao J: miR-34 is associated with poor
prognosis of patients with gallbladder cancer through regulating
telomere length in tumor stem cells. Tumour Biol. 35:150–510. 2014.
View Article : Google Scholar
|
|
20
|
Yadav A, Gupta A, Rastogi N, Agrawal S,
Kumar A, Kumar V and Mittal B: Association of cancer stem cell
markers genetic variants with gallbladder cancer susceptibility,
prognosis, and survival. Tumour Biol. 37:183–844. 2016.
|
|
21
|
Wang X: Identification of cancer stem
cells in gallbladder carcinoma: A platform for the discovery of
novel therapeutic targets. Cancer Biol Ther. 10:119–193. 2010.
View Article : Google Scholar
|
|
22
|
Shi C, Tian R, Wang M, Wang X, Jiang J,
Zhang Z, Li X, He Z, Gong W and Qin R: CD44+
CD133+ population exhibits cancer stem cell-like
characteristics in human gallbladder carcinoma. Cancer Biol Ther.
10:118–190. 2010.
|
|
23
|
Shi CJ, Gao J, Wang M, Wang X, Tian R, Zhu
F, Shen M and Qin RY: CD133(+) gallbladder carcinoma cells exhibit
self-renewal ability and tumorigenicity. World J Gastroenterol.
17:296–971. 2011. View Article : Google Scholar
|
|
24
|
Han T, Xiang DM, Sun W, Liu N, Sun HL, Wen
W, Shen WF, Wang RY, Chen C, Wang X, et al: PTPN11/Shp2
overexpression enhances liver cancer progression and predicts poor
prognosis of patients. J Hepatol. 63:65–60. 2015. View Article : Google Scholar
|
|
25
|
Roccograndi L, Binder ZA, Zhang L, Aceto
N, Zhang Z, Bentires-Alj M, Nakano I, Dahmane N and O'Rourke DM:
SHP2 regulates proliferation and tumorigenicity of glioma stem
cells. J Neurooncol. 135:48–96. 2017. View Article : Google Scholar
|
|
26
|
Sengupta S, Nagalingam A, Muniraj N,
Bonner MY, Mistriotis P, Afthinos A, Kuppusamy P, Lanoue D, Cho S,
Korangath P, et al: Activation of tumor suppressor LKB1 by honokiol
abrogates cancer stem-like phenotype in breast cancer via
inhibition of oncogenic Stat3. Oncogene. 36:570–721. 2017.
View Article : Google Scholar
|
|
27
|
Enyu L, Na W, Chuanzong Z, Ben W, Xiaojuan
W, Yan W, Zequn L, Jianguo H, Jiayong W, Benjia L, et al: The
clinical significance and underlying correlation of pStat-3 and
integrin αvβ6 expression in gallbladder cancer. Oncotarget.
8:1946–9477. 2017. View Article : Google Scholar
|
|
28
|
Kong X, Ma MZ, Zhang Y, Weng MZ, Gong W,
Guo LQ, Zhang JX, Wang GD, Su Q, Quan ZW, et al: Differentiation
therapy: Sesamin as an effective agent in targeting cancer
stem-like side population cells of human gallbladder carcinoma. BMC
Complement Altern Med. 14:2542014. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Jin YP, Hu YP, Wu XS, Wu YS, Ye YY, Li HF,
Liu YC, Jiang L, Liu FT, Zhang YJ, et al: miR-14-p targeting of
ITGA6 suppresses tumour growth and angiogenesis by downregulating
PLGF expression via the PI3K/AKT pathway in gallbladder carcinoma.
Cell Death Dis. 9:1822018. View Article : Google Scholar
|
|
30
|
Mohri D, Ijichi H, Miyabayashi K,
Takahashi R, Kudo Y, Sasaki T, Asaoka Y, Tanaka Y, Ikenoue T,
Tateishi K, et al: A potent therapeutics for gallbladder cancer by
combinatorial inhibition of the MAPK and mTOR signaling networks. J
Gastroenterol. 51:711–721. 2016. View Article : Google Scholar
|
|
31
|
Wang SH, Wu XC, Zhang MD, Weng MZ, Zhou D
and Quan ZW: Upregulation of H19 indicates a poor prognosis in
gallbladder carcinoma and promotes epithelial-mesenchymal
transition. Am J Cancer Res. 6:15–26. 2015.
|
|
32
|
Xiong L, Wen Y, Miao X and Yang Z: NT5E
and FcGBP as key regulators of TGF-1-induced epithelial-mesenchymal
transition (EMT) are associated with tumor progression and survival
of patients with gallbladder cancer. Cell Tissue Res. 355:365–374.
2014. View Article : Google Scholar
|
|
33
|
Zhao S, Cao Y, Liu SB, Wang XA, Bao RF,
Shu YJ, Hu YP, Zhang YJ, Jiang L, Zhang F, et al: The E545K
mutation of PIK3CA promotes gallbladder carcinoma progression
through enhanced binding to EGFR. J Exp Clin Cancer Res. 35:972016.
View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Caldow Pilgrim CH, Groeschl RT, Quebbeman
EJ and Gamblin TC: Recent advances in systemic therapies and
radiotherapy for gallbladder cancer. Surg Oncol. 22:61–67. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Trapp EK, Majunke L, Zill B, Sommer H,
Andergassen U, Koch J, Harbeck N, Mahner S, Friedl TWP, Janni W, et
al: LKB1 pro-oncogenic activity triggers cell survival in
circulating tumor cells. Mol Oncol. 11:1508–1526. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Zhang S, Balch C, Chan MW, Lai HC, Matei
D, Schilder JM, Yan PS, Huang TH and Nephew KP: Identification and
characterization of ovarian cancer-initiating cells from primary
human tumors. Cancer Res. 68:4311–4320. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Wang X, Sun W, Shen W, Xia M, Chen C,
Xiang D, Ning B, Cui X, Li H, Li X, et al: Long non-coding RNA DILC
regulates liver cancer stem cells via IL-6/STAT3 axis. J Hepatol.
64:1283–1294. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Hill DG, Yu L, Gao H, Balic JJ, West A,
Oshima H, McLeod L, Oshima M, Gallimore A, D'Costa K, et al:
Hyperactive gp130/STAT3-driven gastric tumourigenesis promotes
submucosal tertiary lymphoid structure development. Int J Cancer.
Feb 8–2018.Epub ahead of print. View Article : Google Scholar
|
|
39
|
Johnson DE, O'Keefe RA and Grandis JR:
Targeting the IL-6/JAK/STAT3 signalling axis in cancer. Nat Rev
Clin Oncol. 15:234–248. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Jin G, Yang Y, Liu K, Zhao J, Chen X, Liu
H, Bai R, Li X, Jiang Y, Zhang X, et al: Combination curcumin and
(−)-epigallocatechin-3-gallate inhibits colorectal carcinoma
microenvironment-induced angiogenesis by JAK/STAT3/IL-8 pathway.
Oncogenesis. 6:e3842017. View Article : Google Scholar
|
|
41
|
Wang W, Zhan M, Li Q, Chen W, Chu H, Huang
Q, Hou Z, Man M and Wang J: FXR agonists enhance the sensitivity of
biliary tract cancer cells to cisplatin via SHP dependent
inhibition of Bcl-xL expression. Oncotarget. 7:34617–34629.
2016.PubMed/NCBI
|
|
42
|
Takeda K, Noguchi K, Shi W, Tanaka T,
Matsumoto M, Yoshida N, Kishimoto T and Akira S: Targeted
disruption of the mouse Stat3 gene leads to early embryonic
lethality. Proc Natl Acad Sci USA. 94:3801–3804. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
He N, Chen X, Wang D, Xu K, Wu L, Liu Y,
Tao H, Zhao Q, Cao X, Li Y, et al: VE-cadherin regulates the
self-renewal of mouse embryonic stem cells via LIF/Stat3 signaling
pathway. Biomaterials. 158:34–43. 2018. View Article : Google Scholar
|
|
44
|
Schroeder A, Herrmann A, Cherryholmes G,
Kowolik C, Buettner R, Pal S, Yu H, Müller-Newen G and Jove R: Loss
of androgen receptor expression promotes a stem-like cell phenotype
in prostate cancer through STAT3 signaling. Cancer Res.
74:1227–1237. 2014. View Article : Google Scholar
|
|
45
|
Korkaya H, Kim GI, Davis A, Malik F, Henry
NL, Ithimakin S, Quraishi AA, Tawakkol N, D'Angelo R, Paulson AK,
et al: Activation of an IL6 inflammatory loop mediates trastuzumab
resistance in HER2+ breast cancer by expanding the
cancer stem cell population. Mol Cell. 47:570–584. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Jinushi M, Chiba S, Yoshiyama H, Masutomi
K, Kinoshita I, Dosaka-Akita H, Yagita H, Takaoka A and Tahara H:
Tumor-associated macrophages regulate tumorigenicity and anticancer
drug responses of cancer stem/initiating cells. Proc Natl Acad Sci
USA. 108:12425–12430. 2011. View Article : Google Scholar : PubMed/NCBI
|
